DNA Synthesis Key Players and Market Trends Analysis

Top Companies in the DNA Synthesis Market

• Thermo Fisher Scientific
• Integrated DNA Technologies (IDT, Danaher)
• Twist Bioscience
• GenScript Biotech
• Agilent Technologies
• Eurofins Genomics
• Merck KGaA (Sigma-Aldrich)
• Illumina, Inc.
• DNA Script (enzymatic DNA synthesis)
• Brooks Automation (GENEWIZ)
• OriCiro Genomics
• ATUM (formerly DNA2.0)
• Codex DNA (Telesis Bio)
• Blue Heron Biotechnology
• BioCat GmbH
• Genewiz Japan (Azenta Life Sciences)
• Evonetix Ltd.
• Synbio Technologies
• Scarab Genomics
• Creative Biogene

Market Forecast

The global DNA synthesis market size is calculated at US$ 4.62 billion in 2024, grew to US$ 5.43 billion in 2025, and is projected to reach around US$ 23.1 billion by 2034. The market is expanding at a CAGR of 17.42% between 2025 and 2034.

What are the Trends in the DNA Synthesis Market?

Rising collaboration among key players: DNA synthesis is a highly essential part of both the pharma and biotechnology industries; hence, key market players are collaborating in order to provide advanced technologies and procedures to improve DNA synthesis processes.

For instance,

• In March 2025, Elegen, a leader in next-generation DNA manufacturing, partnered with global genomics solutions provider Integrated DNA Technologies (IDT) to provide IDT clients with early access to Elegen's ENFINIATM Plasmid DNA, a lengthy and highly complicated clonal gene synthesis service.
• In March 2025, in order to develop and produce clinically and commercially ready synthetic DNA at the gramme scale, Syngoi Technologies, a leader in the large-scale production of synthetic DNA at the clinical stage, and Ribbon Bio GmbH, the DNA synthesis company, announced that they have started a strategic partnership.

Latest Announcements by Industry Leaders

In May 2025, short DNA fragments have been handcuffing scientists for decades, forcing them to use laborious cloning procedures in their own facilities to piece sequences together, according to Jason T. Gammack, CEO of Ansa Biotechnologies. With a transparent and cooperative service approach, Ansa is already revolutionising the industry by providing longer, more complicated DNA. Our unwavering commitment to enabling researchers to construct without boundaries and innovate without compromise is seen by the quick expansion in our product length, which went from 600 bases a year ago to 7.5 kb more recently and now 50 kb through early access.

Recent Developments in the DNA Synthesis Market

• In September 2025, ENFINIATM IVT Ready DNA has been formally introduced by Elegen, a pioneer in the production of cell-free DNA. This cutting-edge product may be used right away in in vitro transcription (IVT), cutting down on the weeks required to create mRNA-based treatments.
• In May 2025, the DNA synthesis business Ribbon Bio GmbH announced the release of MiroSynthTM DNA, its first commercial product created to satisfy the rising need for intricate and incredibly precise synthetic DNA molecules.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com